Navidea biopharmaceuticals reports first quarter 2022 financial results

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the first quarter for the period ended march 31, 2022. first quarter 2022 highlights and subsequent events continued enrollment into the company's nav3-33 phase 3 trial in rheumatoid arthritis (“ra”) titled “evaluation of tc 99m tilmanocept im
NAVB Ratings Summary
NAVB Quant Ranking